Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Operating Leases (2019 - 2026)

Champions Oncology has reported Operating Leases over the past 8 years, most recently at $3.4 million for Q1 2026.

  • For Q1 2026, Operating Leases fell 47.72% year-over-year to $3.4 million; the TTM value through Jan 2026 reached $3.4 million, down 47.72%, while the annual FY2025 figure was $4.6 million, 23.95% down from the prior year.
  • Operating Leases for Q1 2026 was $3.4 million at Champions Oncology, down from $5.3 million in the prior quarter.
  • Over five years, Operating Leases peaked at $9.2 million in Q3 2022 and troughed at $3.4 million in Q1 2026.
  • A 5-year average of $6.8 million and a median of $6.8 million in 2023 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: surged 48.64% in 2022 and later plummeted 47.72% in 2026.
  • Year by year, Operating Leases stood at $9.0 million in 2022, then decreased by 24.43% to $6.8 million in 2023, then changed by 0.0% to $6.8 million in 2024, then dropped by 22.23% to $5.3 million in 2025, then plummeted by 36.14% to $3.4 million in 2026.
  • Business Quant data shows Operating Leases for CSBR at $3.4 million in Q1 2026, $5.3 million in Q4 2025, and $4.2 million in Q3 2025.